Antibody Drug Conjugates Market is expected to reach US$ 38,077.45 Million by 2031

Cleavable Linker Segment to Bolster Antibody Drug Conjugates Market Growth During 2023–2031

According to our new research study on "Antibody Drug Conjugates Market Forecast to 2031 – Global Analysis – by Technology, Application, Target, and Distribution Channel," the market was valued at US$ 8,105.65 million in 2023 and is expected to reach US$ 38,077.45 million by 2031; it is estimated to record a CAGR of 21.3% during 2023–2031. The antibody drug conjugates market report emphasizes the trends prevalent in the global market, along with drivers and deterrents affecting its growth.

Strategic investments by key players and increase in the availability of approved products are contributing to the antibody drug conjugates market growth. However, manufacturing challenges hamper the market growth. Further, expanding clinical trial pipeline is expected to bring new antibody drug conjugates market trends in the coming years.

Antibody Drug Conjugates Market  Share, by Region, 2023 (%)

Source: The Insight Partners Analysis

Strategic Investments by Key Players Bolsters Antibody-Drug Conjugates Market Size

Strategic investments such as mergers, acquisitions, partnerships, and collaborations among key players in the antibody-drug conjugates market significantly influence its growth and development. These strategies enable companies to pool resources, share expertise, and leverage complementary strengths to enhance their competitive edge in a rapidly evolving landscape. Amid the search for innovative cancer therapies, antibody-drug conjugates have gained attention for their ability to selectively target and destroy cancer cells while sparing healthy tissues, thereby minimizing side effects. Consequently, major pharmaceutical and biotechnology firms are increasingly engaging in strategic alliances to accelerate the development and commercialization of antibody-drug conjugates.

As the market becomes more competitive, companies seek to acquire or merge with other firms that have promising antibody-drug conjugate technologies or candidates in their pipelines. For instance, larger pharmaceutical companies acquire smaller biotech firms specializing in antibody-drug conjugate development to quickly incorporate advanced technologies into their existing product lines. Such acquisitions help the acquiring company enhance its portfolio and gain access to novel linker technologies, payloads, and targeting mechanisms that can improve the efficacy and safety profiles of its therapeutics. In October 2024, GlycoMimetics, Inc. entered into an acquisition agreement with Crescent Biopharma, Inc., a privately held biotechnology company advancing a pipeline of oncology therapeutics designed to treat solid tumors. Upon completion of the transaction, the company plans to operate under the name Crescent Biopharma, Inc. In March 2024, Johnson & Johnson acquired Ambrx Biopharma, Inc., a clinical-stage biopharmaceutical company with a proprietary synthetic biology technology platform, to design and develop next-generation antibody-drug conjugates. In September 2024, Araris Biotech AG, a Swiss oncology and biotechnology company involved in developing next-generation antibody-drug conjugates, announced making an agreement with Innate Pharma. Under the agreement, Innate would assign Araris a portfolio of patents related to its transglutaminase conjugation technology.

The competitive landscape in the antibody-drug conjugates market is characterized by a high level of activity from key players engaging in strategic investments. This dynamism encourages innovation and improvement as companies strive to differentiate their products and establish leadership in the market. The influx of capital investment into oncology attracts new entrants, leading to a more vibrant ecosystem encouraging innovative ideas. Strategic investments through mergers, acquisitions, partnerships, and collaborations play a pivotal role in driving the growth of the antibody-drug conjugates market. These investments create a synergistic environment by enhancing product portfolios, improving manufacturing processes, and fostering innovation to propel the development of effective and targeted cancer therapies.

The antibody drug conjugates market analysis has been carried out by considering the following segments: technology, application, target, distribution channel, and geography. The antibody drug conjugates market, based on technology, is divided into cleavable linker and non-cleavable linker. the cleavable linker segment held a larger share of the market in 2023, and it is expected to register a higher CAGR during 2023–2031. Cleavable linkers use a chemical trigger or inherent properties of antibody structure to release the cytotoxic payload in tumor cells. This technology uses pH sensitivity, glutathione sensitivity, and protease sensitivity mechanisms as chemical triggers. The cleavable linker technology is widely used in developing antibody-drug conjugates. According to the article “Antibody-drug conjugates: Recent advances in linker chemistry,” published in March 2021, over 80% of the approved antibody-drug conjugates are made using cleavable linker technology. Besponsa (inotuzumab ozogamicin) and Adcetris (brentuximab vedotin) are two notable examples of antibody-drug conjugates synthesized using this technology. These conjugates remain comparatively stable for a long time in blood circulation after releasing a hydrophilicity traceless payload. Moreover, cleavable linkers can release the payload intracellularly. With the burgeoning understanding of cleavable linkers, pharmaceutical companies are creating a wider range of antibody-drug conjugates with more potent cytotoxic drugs and better release mechanisms. As a result, a large number of antibody-drug conjugates targeting cancers such as breast cancer, lymphoma, lung cancer, leukemia, and solid tumors are being made available for therapeutic applications. Innovative linker designs are further expanding their applicability, increasing market potential.

The market, based on application, is segmented into blood cancer, brain cancer, breast cancer, ovarian cancer, lung cancer, and others. The breast cancer segment held the largest antibody drug conjugates market share in 2023. The use of antibody-drug conjugates has significantly transformed the approach to breast cancer treatment planning. These conjugates are expected to improve the potency, precision, and safety of breast cancer therapeutics. At present, Kadcyla/T-DM1 (ado-trastuzumab emtansine), Enhertu/T-DXd (trastuzumab deruxtecan), and Trodelvy/SG (sacituzumab govetican) are the commercialized products available in the market to treat triple-negative breast cancer (TNBC) and metastatic breast cancer cases. According to data by the Breast Cancer Research Foundation, published in January 2023, 17 antibody-drug conjugates are in clinical trials; 9 out of these are HER2-directed candidates, which are being studied in different combinations of payloads. The remaining 8 antibody-drug conjugates are being studied in combination with novel antibody targets.

The geographic scope of the antibody drug conjugates market report includes the assessment of the market performance in North America, Europe, Asia Pacific, Middle East and Africa, South and Central America. North America accounted for the largest antibody drug conjugates market share in 2023. The burgeoning incidence of cancer is a leading factor propelling the demand for antibody-drug conjugates in these countries. In addition, market growth in the region is attributed to increasing research and development; rising product approvals; growing awareness about novel conjugates; and a surge in mergers, collaborations, and partnerships.   

Contact Us
 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com